Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial

Sebastian Michels, Bartomeu Massutí, Hans Ulrich Schildhaus, Jeremy Franklin, Martin Sebastian, Enriqueta Felip, Christian Grohé, Delvys Rodriguez-Abreu, Diana S.Y. Abdulla, Helge Bischoff, Christian Brandts, Enric Carcereny, Jesús Corral, Anne Marie C. Dingemans, Eva Pereira, Jana Fassunke, Rieke N. Fischer, Masyar Gardizi, Lukas Heukamp, Amelia InsaAnna Kron, Roopika Menon, Thorsten Persigehl, Martin Reck, Richard Riedel, Sacha I. Rothschild, Andreas H. Scheel, Matthias Scheffler, Petra Schmalz, Egbert F. Smit, Meike Limburg, Mariano Provencio, Niki Karachaliou, Sabine Merkelbach-Bruse, Martin Hellmich, Lucia Nogova, Reinhard Büttner, Rafael Rosell, Jürgen Wolf*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

85 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial'. Together they form a unique fingerprint.

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science